C3 and systemic sclerosis: Evidence from the literature suggests that CS activation might be involved in the pathophysiology of SSc: abnormal local complement activation has been described in skin lesions of SSc patients, and C3 and/or C4 hypocomplementemia is present in ∼15% of patients with SSc (49, 50).